Treatment of unresectable or metastatic osteosarcoma with cisplatin or cisplatin–doxorubicin
- 15 October 1985
- Vol. 56 (8) , 1930-1933
- https://doi.org/10.1002/1097-0142(19851015)56:8<1930::aid-cncr2820560806>3.0.co;2-u
Abstract
Responses and toxicity after treatment with cisplatin and cisplatin–doxorubicin were compared in two groups of patients with unresectable or metastatic osteosarcoma. Complete or partial responses developed in 3 of 18 individuals treated with cisplatin, and in 5 of 19 after the two‐drug combination. Hematologic and gastrointestinal complications were more frequent and severe in patients who received both agents. The combined use of cisplatin and doxorubicin is justified for patients with unresectable or metastatic osteosarcoma at diagnosis because of the potential therapeutic benefits for these individuals. Cancer 56: 1930‐1933, 1985.This publication has 9 references indexed in Scilit:
- Hearing loss in children receiving cisplatin chemotherapyThe Journal of Pediatrics, 1983
- Preoperative chemotherapy for osteogenic sarcoma:Selection of postoperative adjuvant chemotherapy based on the response of the primary tumor to preoperative chemotherapyCancer, 1982
- Clinical evaluation of sequentially scheduled cisplatin and vm26 in neuroblastoma: Response and toxicityCancer, 1981
- Improved chemotherapy for ovarian cancer with cis-diamminedichloroplatinum and adriamycinCancer, 1981
- Adjuvant adriamycin and cis-diamminedichloroplatinum (cis-platinum) in primary osteosarcomaCancer, 1981
- Cis-dichlorodiammine platinum and adriamycin therapy for advanced gynecological and genitourinary neoplasmsCancer, 1980
- Chemotherapy of Osteosarcoma — An OverviewPublished by Springer Nature ,1980
- Doxorubicin in DisseminatedPublished by American Medical Association (AMA) ,1972
- Clinical Trials with Adriamycin. Results of Three-Years StudyPublished by Springer Nature ,1972